To Study the Effect of Swertiamarin in Animal Model of Huntington’s Disease

Objective: The Data suggest that swertiamarin has antioxidant activity and they modulate neurotoxicity induced oxidative impairments in the brain and can be effectively employed as a neuroprotective. The preclinical findings obtained in the present study may provide a rationale for clinical trials of swertiamarin in humans with HD. Swertiamarin is a safe and well tolerated drug used as nutrient so can be administered for a long period of time. Method: Adult male Wistar rats born and reared in the Animal House of the Agnihotri College of Pharmacy, Wardha, India was used in the present study. Young healthy male rats (250–300 g) were group housed (Six per cage) and maintained at 23±2◦ C under 12:12 hrs light (08:00–20:00 h)/dark cycle with free access to rodent chow and tap water. The animal studies were approved by the Institutional Animal Ethics Committee, constituted for the purpose of control and supervision of experimental animals by Ministry of Environment and Forests, Government of India, New Delhi, India. Animals were naive to drug treatments and experimentation at the beginning of all studies. All tests were conducted between 08:00 and13:00 h. The drug was tested in doses of 25-100 mg/kg ip. Unless stated otherwise, the data given indicate the effect of swertiamarin in doses of 50 mg/kg ip and a pretreatment time of 1 hr. Result: These findings demonstrate that daily treatment with swertiamarin protects against various behavioral and biochemical alterations induced by 3-nitropropionic acid in rats. However, further studies are required to understand the exact mechanism involved in its neuroprotective role in this animal model of Huntington's disease. Conclusion: Swertiamarin treatment protects behavioral changes, and significantly attenuated oxidative damage and improved mitochondrial complexes enzyme activities in different regions (striatum, cortex and hippocampus) of rat brain against 3-NP induced neurotoxicity. The results show that more effective than Swertiamarin and thus it could be used as an effective therapeutic agent in the management of Huntington's disease and related conditions.